What is the difference between EUDAMED and Swissdamed?

EUDAMED and Swissdamed are two distinct medical device databases serving different regulatory jurisdictions. EUDAMED is the European Union’s centralized database for medical devices and IVDs, while Swissdamed is Switzerland’s national database created after the breakdown of the EU–Switzerland Mutual Recognition Agreement. Both require mandatory registration but have different timelines, requirements, and market access implications for medical device manufacturers.

What Are EUDAMED and Swissdamed and Why Do They Matter?

EUDAMED and Swissdamed are regulatory compliance databases that serve as gatekeepers for medical device market access in their respective jurisdictions. Understanding their core functions and significance is essential for manufacturers operating in European markets:

• Regulatory framework support – EUDAMED supports the EU’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), while Swissdamed operates under Switzerland’s Medical Devices Ordinance (MedDO) and In Vitro Diagnostic Devices Ordinance (IvDO)
• Market access requirements – Both databases represent mandatory pathways to market access, meaning manufacturers cannot legally distribute medical devices without proper registration
• Post-market surveillance capabilities – These systems support ongoing regulatory oversight, incident reporting, and market surveillance activities throughout product lifecycles
• Digital regulatory infrastructure – Both databases modernize regulatory processes through centralized data management and electronic submission systems

These databases matter because they fundamentally control market access and ongoing compliance obligations. The European Commission officially confirmed on November 27, 2025, that four key EUDAMED modules are now fully functional following an independent audit under Article 34(2) MDR. Swissdamed emerged as Switzerland’s response to regulatory independence, mirroring EUDAMED’s structure while serving the distinct needs of the Swiss market. Together, these systems represent the new digital foundation for medical device regulation across European markets.

What’s The Difference Between EUDAMED and Swissdamed Registration Requirements?

The registration requirements differ primarily in scope and specific data elements, though both databases share similar structural foundations. Both systems use two-module approaches requiring Actor registration for economic operators before Device registration for products can begin.

Actor registration requirements show clear jurisdictional differences:

• EUDAMED scope – covers EU-based manufacturers, authorized representatives, importers, and distributors across all member states with broad geographical reach
• Swissdamed scope – focuses on Swiss-based manufacturers, CH-REPs, importers, and Swiss-based procedure pack producers with Switzerland-specific requirements
• Access limitations – non-Swiss manufacturers cannot directly access Swissdamed and must work through their CH-REP for all registration activities
• Regulatory alignment – each system aligns with its respective regulatory framework while maintaining similar core data structures

Device registration requirements reveal both similarities and key differences that reflect each system’s regulatory environment. Both databases require Basic UDI and UDI-DI data using largely identical data elements, but include jurisdiction-specific requirements. Swissdamed incorporates Swiss market status indicators, Swiss single registration numbers (CHRN), mandatory CH-REP details, and enhanced record versioning capabilities. EUDAMED includes EU-specific elements like market status tracking across individual member states and broader multi-jurisdictional compliance data. Understanding these differences ensures manufacturers prepare appropriate data sets for each system while leveraging similarities to streamline preparation efforts.

How Do EUDAMED and Swissdamed Timelines and Implementation Differ?

The implementation timelines for EUDAMED and Swissdamed follow different schedules, reflecting their separate regulatory development paths and distinct market priorities. Understanding these timelines is crucial for strategic planning and resource allocation:

• EUDAMED mandatory dates – Actor registration becomes mandatory on May 28, 2026, with device registration required for all products first placed on the EU market after that date
• Swissdamed accelerated timeline – Actor registration became mandatory on August 6, 2024, with device registration mandatory from July 1, 2026, and a transition period ending December 31, 2026
• Fee structures – Swissdamed charges $300 per device notification starting July 2026, while EUDAMED fees vary by member state and registration type
• Voluntary registration periods – both systems offer early registration opportunities to avoid deadline bottlenecks and technical issues

The staggered implementation creates both opportunities and challenges for manufacturers operating in multiple markets. EUDAMED’s later mandatory date provides more preparation time but affects the larger EU market, while Swissdamed’s compressed timeline requires immediate attention for Swiss market access. The Vigilance module for EUDAMED is anticipated to become mandatory in Q2 2027, subject to successful audit completion, adding another layer of timeline complexity. Manufacturers benefit from completing voluntary registrations early in both systems, allowing time for technical validation and process refinement before mandatory deadlines create system bottlenecks.

Which Database Should Your Medical Device Company Prioritize?

Your prioritization strategy depends entirely on your target markets, regulatory obligations, and resource capabilities. Companies marketing devices in both the EU and Switzerland must register in both databases, as neither system provides cross-recognition, but timing and resource allocation can be strategically managed.

Strategic prioritization factors include several key considerations:

• Market size and revenue impact – the EU’s larger market typically justifies prioritizing EUDAMED preparation, while companies with significant Swiss operations may prioritize Swissdamed
• Timeline pressures – Swissdamed’s earlier device registration deadline (July 1, 2026) versus EUDAMED’s May 28, 2026 Actor registration requirement creates different urgency levels
• Data preparation synergies – both systems use similar data structures, allowing parallel preparation work that reduces overall compliance burden
• Resource allocation efficiency – staggering registration activities prevents overwhelming internal teams while ensuring deadline compliance
• Authorized representative coordination – ensuring your EU AR and CH-REP can support simultaneous registrations without conflicts or delays

The most effective approach often involves integrated preparation addressing both databases simultaneously while respecting each system’s unique requirements and deadlines. Since Swissdamed’s design leverages EUDAMED’s structure with largely identical data elements, manufacturers can maximize preparation efficiency across both systems. This integrated strategy reduces overall compliance costs, ensures consistent data quality, and provides flexibility to adjust priorities based on changing market conditions or regulatory developments. Success requires early planning, adequate resource allocation, and coordination between regulatory teams and authorized representatives in both jurisdictions.

How MedEnvoy Global Helps With EUDAMED and Swissdamed Registration

MedEnvoy Global provides comprehensive regulatory support to help medical device manufacturers navigate both EUDAMED and Swissdamed registration requirements efficiently and compliantly. Our integrated approach addresses the unique challenges of dual-database compliance while maximizing preparation synergies:

• End-to-end registration services – complete Actor and Device registration support for both databases, including data preparation, submission management, and post-registration maintenance
• Strategic timeline coordination – expert guidance on prioritization strategies that balance market importance, regulatory deadlines, and resource constraints
• Authorized representative services – qualified EU AR and CH-REP services ensuring seamless coordination between both registration systems
• Data optimization strategies – leveraging similarities between databases to reduce preparation time and costs while ensuring jurisdiction-specific compliance
• Ongoing compliance support – post-registration maintenance, updates, and regulatory monitoring to maintain market access in both jurisdictions

Ready to streamline your EUDAMED and Swissdamed registration strategy? Contact MedEnvoy Global today to learn how our comprehensive regulatory services can ensure compliant market access across European and Swiss markets while optimizing your compliance investment.

Related Articles

• What is the EUDAMED deadline for medical devices?
• How do I manage multiple device registrations in EUDAMED?
• Do Legacy Devices Need a Swiss Authorized Representative?
• Can someone else register my devices in EUDAMED for me?
• What Technical Files Are Required in Europe?